BUELACH, Switzerland,
26
April
2018
|
00:00
Europe/Amsterdam

Charing Cross Symposium 2018: Real World DCB Registry BIOLUX P-III Shows Excellent 12-Month Results in the Full Cohort and BTK Subgroup

BIOTRONIK announced the latest results of three lower limb clinical trials – BIOLUX P-III, BIOFLEX PEACE and BIOLUX 4EVER

References:

1Brodmann M. Certificate of Merit Winner CX 2017 - Real-world experience with a paclitaxel-coated balloon for the treatment of atherosclerotic infrainguinal arteries. Twelve-month results of the BIOLUX P-III all-comers registry for the full cohort. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02276313

2Not currently available in the United States.

3Tepe G. BIOLUX P-III, Passeo-18 Lux registry: 12-month Results in BTK. Presented at: Charing Cross 2018. April 24, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02276313

4Lichtenberg M, BIOFLEX PEACE all-comer registry. Prospective multicenter registry for the treatment of stenosis and occlusion of the superficial femoral artery using the 4F Pulsar-18 stent. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom.

5Deloose K. BIOLUX 4EVER physician-initiated, prospective, multicenter, controlled trial investigating the efficacy of endovascular treatment of femoropopliteal arterial stenotic disease with Passeo-18 Lux drug-coated balloon and Pulsar-18 stent. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02211664

 

About BIOTRONIK:

BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.